Munich, 12. February, 2008 - Definiens, the number one Enterprise Image Intelligence Company and Cenix BioScience GmbH, the leading specialist in advanced high throughput (HT) RNA interference (RNAi)-based research services, announced today that they have expanded their mutual licensing agreement. This strategic decision confirms the heightened commitment of Cenix to the use of the Definiens technology within its organization. Resulting from the findings of an internal review Definiens Cellenger® was reselected as the best available application to support Cenix in the development and implementation of high content (HC) microscopy assays for HT-RNAi studies in cultured human and rodent cells.
Definiens Cellenger is Definiens advanced application for high content analysis that enables the reliable and fully automated extraction of data from images used in cell-based assays. It allows Cenix to analyze structures of interest even in complex images with high accuracy. The flexible and platform-independent application automates and standardizes the companys image analysis processes - of particular use with multi-parametric cell-based assays. For this innovative technology, Definiens gained the 2007 Frost & Sullivan Technology Leadership Award in the US high-content screening market, which is based on a detailed analysis of the high content screening market executed by Frost & Sullivan.
With Definiens Cellenger Cenix is able to handle the most challenging demands of image analysis tasks, covering every assay development need. The application will be integrated into the existing HT/HC-RNAi-based research infrastructure at Cenix, enabling the widest possible range of advanced microscopy-based assays in its research service offerings.
Dr. Michael Hannus, Group Leader, Cell-based Discovery & Validation at Cenix BioScience, said After we tested and reviewed the available high content screening software, it became obvious that there is no other solution out there that can support us in the extremely challenging image analysis tasks we perform for our customers.
Cenix BioScience provides research services to the life science industry and the academic community, focusing on the combination of HT-RNAi with HC assays in human and rodent cells. In its efforts to further strengthen its capabilities in microscopy-based screening and automated image analysis, Cenix BioScience reviewed a wide range of image analysis solutions offered by academia and industry.
We are pleased with Cenixs decision to intensify the use of our product in its laboratories, stated Rene Hermes, Vice President Marketing, Definiens. Its decision is recognition of the unmatched possibilities that our technology offers to customers for developing automated image analysis applications.
About Cenix BioScience GmbH
Cenix BioScience GmbH is a pioneer and global leader in the convergence of high throughput (HT), genomics-driven applications of RNA interference (RNAi) with high content, multi-parametric cell-based assays. Founded in 1999 as the first biotechnology company specializing in HT-RNAi, Cenix has accumulated unparalleled depth and breadth of experience in this field, using human and rodent cell models in a wide range of disease indications, including oncology, atherosclerosis, diabetes, obesity, neurodegenerative disorders and infectious diseases such as malaria. Cenix offers its unique expertise to industry and academic researchers through fully customizable research services, focusing on the discovery and validation of novel therapeutic drug targets and the analysis of drug mechanisms of action. Please contact Cenix or visit the companys web site www.cenix-bioscience.com for more information.
Definiens in Life Sciences
By automating image analysis on an enterprise level, Definiens supports Life Science organizations to analyze and interpret vast numbers of images accurately and consistently. Definiens improves the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, enabling high-content screening, digital pathology and translational medicine.
Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale, from microscopic cell structures to satellite images. The Definiens Cognition Network Technology®, developed by Nobel laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Life and Earth sciences markets. The technology is modeled on the powerful human cognitive perception processes to extract intelligence from images. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better business decisions. The company is headquartered in Munich, Germany and has offices throughout the United States. Further information is available at www.definiens.com
Definiens, Definiens Cellenger, Definiens Cognition Network Technology, Definiens eCognition, Enterprise Image Intelligence and Understanding Images are trademarks or registered trademarks of Definiens.
Rene Hermes, Vice President Marketing
+49 (0)89 231180-11
Lucy Turpin Communications
Eva Hildebrandt, PR & MarCom Manager
+49 (0)89 417761-14
Für den Inhalt der Pressemitteilung ist der Einsteller, Veronika Mallmann, verantwortlich.
Es wurde noch kein Kommentar zu diesem Thema abgegeben.